MEMPHIS, Tenn. (May 24, 2006) — The Stuttering Foundation of America today welcomed news that clinical trials of the drug pagoclone showed significant speech improvements for people who stutter.
"We were particularly pleased to learn that pagoclone does not appear to have any serious side effects, unlike some drugs used in the past," says Jane Fraser, president of the Stuttering Foundation.
The drug's manufacturer, Indevus Pharmaceuticals, announced the results today (see the announcement on the Stuttering Foundation's Web site, www.stutteringhelp.org).
The Stuttering Foundation reached more than 800,000 people who stutter in 101 countries in the past year. If pagoclone is approved, it will be another effective tool to treat this frustrating and embarrassing disorder that affects millions worldwide.